GLP-1-based therapies yet to reach their peak potential

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1656, 2008-01, pp. : 3-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Will GLP-1-based therapies substitute sulfonylureas?

By  

Inpharma, Vol. 1, Iss. 1607, 2007-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Pleiotropic Effects of Glucagon-like Peptide-1 (GLP-1)-Based Therapies on Vascular Complications in Diabetes

By  

Current Pharmaceutical Design, Vol. 17, Iss. 38, 2011-01 ,pp. : 4379-4385

Bentham Science Publishers

Access to resources Recommend Favorite

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

By Hölscher Christian  

CNS Drugs, Vol. 26, Iss. 10, 2012-10 ,pp. : 871-882

Adis International

Access to resources Recommend Favorite

GLP-1 7-36 amide: potential in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1247, 2000-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies

By Bley Keith R  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1445-1456

Informa Healthcare

Access to resources Recommend Favorite